.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BX04_Romiplostim.Romiplostim .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BX04_Romiplostim.Romiplostim| name: | Romiplostim |
| ATC code: | B02BX04 | route: | subcutaneous |
| n-compartments | 2 |
Romiplostim is a thrombopoietin receptor agonist (TPO-RA) that stimulates platelet production by binding to and activating the thrombopoietin receptor (c-Mpl). It is approved for the treatment of chronic immune (idiopathic) thrombocytopenia purpura (ITP) in adult patients who are refractory to other treatments such as corticosteroids, immunoglobulins, or splenectomy.
Population pharmacokinetics in adult patients with chronic ITP, as described in clinical trials and modeling reports. Typically, a two-compartment model with subcutaneous administration is used. Parameters reflect mean estimates across adult patient populations.
Wang, YM, et al., & Chow, AT (2010). Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. The AAPS journal 12(4) 729–740. DOI:10.1208/s12248-010-9234-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20963535